Clinical trials: Disorder, Mood
Parkinson's Disease, Depression
rTMS for Motor and Mood Symptoms of Parkinson's Disease
The purpose of this study is to determine if repetitive transcranial magnetic stimulation (rTMS), a method of noninvasive brain stimulation) is effective in the treatment of the motor (movement) and mood symptoms due to…
- Trial name
- MASTER-PD (NCT01080794)
- Testing
- Repetitive transcranial magnetic stimulation (rTMS)
- Where
- 6 sites in United States, Canada
- Volunteers
- 61 people
- Sponsor
- Beth Israel Deaconess Medical Center
Mood Disorder, Anxiety Disorders
Intranasal Administration of Neuropeptide Y in Healthy Male Volunteers
There is growing evidence that neuropeptides act as neuronal messengers in the brain and have diverse functions that may include the regulation of mood and behavior.
- Trial name
- NPY (NCT00748956)
- Testing
- Low dose NPY, High dose NPY
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Dennis Charney
Mental Health Issues, Bipolar Disorder
Music Therapy Advocacy Recording Intervention (MTAR) on Internalized Stigma
This study will use a systematic music therapy intervention on patients with mental illness trying to help them with their internalized stigma.
- Conditions
- Mental Health Issues, Bipolar Disorder, Depressive, Schizophrenia Spectrum and Other Psychotic Disorders
- Trial name
- NCT05723328
- Testing
- Group Music Therapy Advocacy Recording Intervention (MTAR)
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Hackensack Meridian Health
Major Depressive Disorder, Depression
Study to Treat Major Depressive Disorder (MDD) With a New Medication
The purpose of this study is to test the antidepressant effects of Ezogabine in major depressive disorder (MDD). The investigators also aim to determine the safety and tolerability Ezogabine in patients with MDD.
- Trial name
- NCT02149836
- Testing
- ezogabine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Major Depressive Disorder
Efficacy and Safety of Cranial Electrical Stimulation (CES) for Major Depressive Disorder (MDD)
The purpose of this study is to see if using Cranial Electrical Stimulation (CES) helps improve symptoms of major depressive disorder (MDD).
- Trial name
- NCT01325532
- Testing
- Active CES
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
Safety and Efficacy Study Comparing ETS6103 With Amitriptyline in the Treatment of Major Depressive Disorder (MDD)
To demonstrate that the antidepressant activity of ETS6103 is not inferior to amitriptyline in subjects who have an unsatisfactory response to / are resistant to treatment with SSRIs.
- Trial name
- ETS6103-003 (NCT02014363)
- Testing
- ETS6103 (low dose), ETS6103 (high dose), Amitriptyline
- Where
- United Kingdom
- Volunteers
- 164 people
- Sponsor
- e-Therapeutics PLC
Treatment Resistant Depression, Major Depressive Disorder
Optimizing Outcomes of Treatment-Resistant Depression in Older Adults
The purpose of this research study is to assess which antidepressants work the best in older adults who have treatment-resistant depression (TRD).
- Conditions
- Treatment Resistant Depression, Major Depressive Disorder, Treatment-Refractory Depression, Late Life Depression
- Trial name
- OPTIMUM (NCT02960763)
- Testing
- Aripiprazole Augmentation, Bupropion Augmentation, Switch to bupropion
- Where
- 5 sites in United States, Canada
- Volunteers
- 742 people
- Sponsor
- Washington University School of Medicine
Major Depressive Disorder
Brain GABA Levels and Treatment Response in Major Depressive Disorder
This study will evaluate changes in brain gamma-aminobutyric acid (GABA) levels due to treatment with escitalopram in people with major depressive disorder.
- Trial name
- NCT00464711
- Testing
- Escitalopram
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Depressive Disorder, Major
The Role Of Omega-3 Fatty Acids In Adolescent Depression
The purpose of this study is to examine the effects of a 10-week Omega-3 Fatty Acid treatment phase on brain chemistry of adolescents with major depressive disorder (MDD) using proton magnetic resonance imaging.
- Trial name
- NCT00962598
- Testing
- Omega 3 Fatty Acids, Corn oil
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Major Depressive Episode, Bipolar Depression
NeoSync TMS Treatment for Bipolar I Depression
This study is designed to evaluate the safety and preliminary efficacy of synchronized transcranial magnetic stimulation (sTMS) using the NeoSync EEG Synchronized TMS device (NEST) in subjects with Bipolar Disorder type I in a…
- Conditions
- Major Depressive Episode, Bipolar Depression, Bipolar Disorder, Mood Disorders
- Trial name
- NESTTBID (NCT02839798)
- Testing
- NEST (NeoSync EEG Synchronized TMS)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Butler Hospital
Seasonal Affective Disorder
Research Study of Treatment for Winter Depression With Different Colors of Light
The specific aim of this study is to test the hypothesis that light stimuli concentrated around 467 nm will evoke a significantly stronger therapeutic response in SAD patients compared to light stimuli concentrated around 657 nm…
- Trial name
- NCT00269633
- Testing
- Blue Light Box 467 nm, Red Light Box 657 nm
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Thomas Jefferson University
Treatment Resistant Depression
Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression (SAINT-TRD)
This study evaluates an accelerated schedule of theta-burst stimulation using a transcranial magnetic stimulation device for treatment-resistant depression.
- Trial name
- aTBS (NCT03068715)
- Testing
- Active TBS-DLPFC, Open label TBS-DLPFC
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Stanford University
Bipolar Depression
Medication, Weight Gain and GI Hormones
This is an 8 week study that compares two medications. One medication is olanzapine (5-20 mg daily) whereas the other medication is an orally disintegrating medication.
- Trial name
- NCT00384332
- Testing
- orally-disintegrating olanzapine, regular olanzapine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University
Major Depressive Disorder
A Study Comparing Duloxetine and Placebo in Assessing Energy and Vitality in Major Depressive Disorder (MDD) Patients
Study F1J-US-HMFS comprises two identical multicenter, 9-month, randomized, placebo-controlled, double-blind, trials (HMFSa and HMFSb).
- Trial name
- NCT00536471
- Testing
- Duloxetine hydrochloride
- Where
- 47 sites in United States, Puerto Rico
- Volunteers
- 776 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
Biological Markers of Response to Treatment in Major Depressive Disorder
The purpose of this study is to find out if two tests are useful in predicting whether someone with depression will get better when he or she is treated with an FDA approved antidepressant medication (either citalopram or…
- Trial name
- NCT00361218
- Testing
- open-label selective serotonin reuptake inhibitor (SSRI)
- Volunteers
- 72 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder (MDD)
Switching From Generic Selective Serotonin Reuptake Inhibitors (SSRIs) and Selective Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) to Three Different Dose Initiation Strategies With Vilazodone
This is an 8-week, randomized, double blind, parallel group, 3-arm trial to compare 10 mg/day, 20 mg/day and 40 mg/day as starting doses of vilazodone following a switch from generic SSRIs and SNRIs.
- Trial name
- NCT02015546
- Testing
- Vilazodone
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Duke University
Major Depressive Disorder
Imaging Dopamine Release in Depression
This study aims to determine whether ventral striatal dopamine release is a mechanism of reward motivation in major depression, whether dopamine release is low in depression, and whether DA release and reward motivation predict…
- Trial name
- NCT02033369
- Testing
- Pramipexole
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Bipolar Disorder
Lithium and Divalproex for the Treatment of Comorbid Rapid Cycling Bipolar Disorder and Substance Abuse Disorder
This study will determine the efficacy and safety of combination therapy with divalproex and lithium for treating mania in people with rapid cycling bipolar disorder and a substance abuse disorder.
- Trial name
- NCT00194129
- Testing
- Lithium, Divalproex
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University Hospitals Cleveland Medical Center
HIV Infections, Schizophrenia
Effectiveness of the Screen, Test, Immunize, Reduce Risk, and Refer (STIRR) Intervention for People With Both a Mental and Substance Abuse Disorder
This study will determine the effectiveness of the STIRR (Screen, Test, Immunize, Reduce risk, and Refer) intervention in increasing rates of testing, immunization, referral, and treatment for blood-borne diseases, such as…
- Conditions
- HIV Infections, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT00316303
- Testing
- Twinrix, Enhanced treatment as usual
- Where
- United States
- Volunteers
- 236 people, healthy volunteers welcome
- Sponsor
- Dartmouth-Hitchcock Medical Center
Persistent Depressive Disorder
Behavioral Activation (BA) for Medication-responsive Chronically Depressed Patients With Impaired Social Functioning
The investigators aimed to assess the ability of a modified version of Behavioral Activation for occupational and social improvement to produce change in: 1. social adjustment, 2. work functioning, 3. avoidance behavior and 4.
- Trial name
- NCT01783080
- Testing
- Behavioral Activation for return to work
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- New York State Psychiatric Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.